SIETES :: 92257 citas

Resultados de la búsqueda por BIOTECNOLOGÍA REFINAR BÚSQUEDA

1.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

2.

Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]

3.

Anónimo. Roche denies Hemlibra caused deaths of five patients, share prices fall. DIA Daily 2018:12. [Ref.ID 102487]

4.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

5.

Anónimo. Arthritis drug prices rise 70 percent in three years despite increased competition. DIA Daily 0:1. [Ref.ID 102183]

6.

Abbasi J. First phase 1 trial of a prophylactic mRNA vaccine reported. JAMA 2017;318:2173. [Ref.ID 102169]

7.

Anónimo. Semma Therapeutics raises $114 million for new diabetes treatment. DIA Daily 2017:1. [Ref.ID 102151]

8.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

9.

Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]

10.

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]

11.

Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 2017;318:626-36. [Ref.ID 102056]

12.

Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]

13.

Anónimo. Ranibizumab, bévacizumab ou aflibercept par voie intravitréenne: thromboses. Prescrire 2017;37:509-11. [Ref.ID 102009]

14.

Anónimo. Daratumumab en monothérapie et myélome multiple en rechute et réfractaire. Prescrire 2017;37:491-3. [Ref.ID 102005]

15.

Anónimo. Necitumumab et cancer bronchique inopérable ou métastasé. Prescrire 2017;37:489-91. [Ref.ID 102004]

16.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]

17.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28. [Ref.ID 101926]

18.

Anónimo. PhRMA, BIO increased spending on federal lobbying. DIA Daily 2017:1. [Ref.ID 101918]

19.

Lillicrap D. Bispecific antibody therapy in hemophilia. N Engl J Med 2017:10 de julio. [Ref.ID 101912]

20.

Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]